GT Biopharma, Inc.

GTBP

US36254L3087

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
3.53 ^USD	-4.08%		-36.96%	-53.86%

May. 21	Top Midday Decliners	MT
May. 21	GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	MT

GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 16, 2022 at 09:01 am EDT

GT Biopharma, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 5.44 million compared to USD 29.68 million a year ago. Basic loss per share from continuing operations was USD 0.17 compared to USD 1.83 a year ago.

Latest news about GT Biopharma, Inc.

Top Midday Decliners	May. 21	MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	May. 21	MT
Top Premarket Gainers	May. 20	MT
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	Feb. 01	MT
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	Dec. 04	CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	Nov. 06	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index	23-06-23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Growth Index	23-06-23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Growth Index	23-06-23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index	23-06-23	CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
GT Biopharma, Inc. Announces Board Changes	23-05-04	CI
Certain Warrants of GT Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 5-APR-2023.	23-04-04	CI
Certain Common Stock of GT Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 5-APR-2023.	23-04-04	CI
North American Morning Briefing : Traders Await -3-	23-03-31	DJ
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
North American Morning Briefing : Stock Futures -2-	23-03-24	DJ
Beyond Air Affiliate Beyond Cancer Names Gavin Choy Chief Operating Officer	23-01-30	MT
EF Hutton Starts GT Biopharma at Hold With $2 Price Target	23-01-05	MT
GT Biopharma to Sell 6.5 Million Shares and Warrants, Expects Gross Proceeds of $6.5 Million	22-12-30	MT
Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer	22-12-14	CI

Chart GT Biopharma, Inc.

Duration

Period

More charts

Company Profile

GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system. The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).

Sector

Pharmaceuticals

Calendar

2024-06-25 - Annual General Meeting

More about the company

	1st Jan change	Capi.
GT BIOPHARMA, INC.	-53.86%	7.61M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.17%	238B
NOVARTIS AG	+7.02%	204B
ROCHE HOLDING AG	-6.54%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B

Other Pharmaceuticals

GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Pharmaceuticals

GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

Latest news about GT Biopharma, Inc.

Chart GT Biopharma, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals